Drug intelligence / Profile preview

eras-12

Development stage: Preclinical
Lead developer: Erasca
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

ERAS-12 is an EGFR D2/D3 bispecific monoclonal antibody under discovery and preclinical development by Erasca, intended to inhibit wildtype EGFR signaling mediated by overexpression of EGFR, which may play a role in cancer therapy pathways[1][9]. By binding two distinct domains of EGFR, ERAS-12 is designed to potentially address escape routes in RAS/MAPK pathway signaling, which are implicated in the development of resistance to existing therapies in RAS/MAPK pathway-driven cancers.

Targets

EGFR domain II (EGFR dimerization domain II)Epidermal growth factor receptor (EGFR) domain III

Beyond the preview

Go deeper on eras-12.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on eras-12.

Explore the full profile